Stock, pipeline and biotech catalyst intelligence
Market expectations
Street view at a glance
The average target implies 113.5% upsideTargets are estimates—not guarantees—and can change after company updates.Wall Street consensus
BuyBased on 3 analyst opinionsPrice-target range
$10.33Company profile
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.